Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.

MLA

Mahipal, Amit, et al. “Tumor-Derived Interleukin-10 as a Prognostic Factor in Stage III Patients Undergoing Adjuvant Treatment with an Autologous Melanoma Cell Vaccine.” Cancer Immunology, Immunotherapy, vol. 60, no. 7, July 2011, pp. 1039–45. EBSCOhost, https://doi.org/10.1007/s00262-011-1019-1.

APA

Mahipal, A., Terai, M., Berd, D., Chervoneva, I., Patel, K., Mastrangelo, M., & Sato, T. (2011). Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunology, Immunotherapy, 60(7), 1039–1045. https://doi.org/10.1007/s00262-011-1019-1

Chicago

Mahipal, Amit, Mizue Terai, David Berd, Inna Chervoneva, Kashyap Patel, Michael Mastrangelo, and Takami Sato. 2011. “Tumor-Derived Interleukin-10 as a Prognostic Factor in Stage III Patients Undergoing Adjuvant Treatment with an Autologous Melanoma Cell Vaccine.” Cancer Immunology, Immunotherapy 60 (7): 1039–45. doi:10.1007/s00262-011-1019-1.